Grifols
- Country
- 🇪🇸Spain
- Ownership
- Subsidiary, Public
- Established
- 1940-01-01
- Employees
- 23.7K
- Market Cap
- $6.8B
- Website
- http://www.grifols.com
- Introduction
Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.
Clinical Trials
55
Trial Phases
4 Phases
Drug Approvals
78
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (55 trials with phase data)• Click on a phase to view related trials
A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
- Conditions
- HypogammaglobulinemiaBacterial InfectionsB-cell Chronic Lymphocytic LeukemiaMultiple MyleomaNon-Hodgkin Lymphoma
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-12-09
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Grifols Therapeutics LLC
- Target Recruit Count
- 386
- Registration Number
- NCT05645107
- Locations
- 🇺🇸
GC2202 Decentralized Study Site 114, Morrisville, North Carolina, United States
🇧🇦GC2202 Study Site 702, Banja Luka, Bosnia and Herzegovina
🇧🇦GC2202 Study Site 703, Mostar, Bosnia and Herzegovina
A Study to Evaluate the Safety and Efficacy of C19-IG 20% in SARS-CoV-2 Infected Asymptomatic Ambulatory Outpatients
- Conditions
- COVID-19Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection
- Interventions
- Biological: C19-IG 20%
- First Posted Date
- 2021-04-19
- Last Posted Date
- 2022-12-05
- Lead Sponsor
- Grifols Therapeutics LLC
- Target Recruit Count
- 465
- Registration Number
- NCT04847141
- Locations
- 🇪🇸
CAP Gornal, L'Hospitalet de Llobregat, Barcelona, Spain
🇪🇸CAP Navàs, Navàs, Barcelona, Spain
🇪🇸CAP Sant Fèlix, Sabadell, Barcelona, Spain
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants with Alpha1-Antitrypsin Deficiency
- Conditions
- Alpha1-Antitrypsin Deficiency
- Interventions
- Biological: Liquid Alpha1-Proteinase Inhibitor (Human)
- First Posted Date
- 2021-01-25
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- Grifols Therapeutics LLC
- Target Recruit Count
- 16
- Registration Number
- NCT04722887
- Locations
- 🇺🇸
Dignity Health-St. Joseph's Hospital & Medical Center, Phoenix, Arizona, United States
🇺🇸UCLA Medical Center, Los Angeles, California, United States
🇺🇸University of Florida, Gainesville, Florida, United States
A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participants and Loading/Maintenance Dosing in Treatment-Naïve Participants With Primary Immunodeficiency
- Conditions
- Primary Immunodeficiency
- First Posted Date
- 2020-09-28
- Last Posted Date
- 2023-09-29
- Lead Sponsor
- Grifols Therapeutics LLC
- Target Recruit Count
- 33
- Registration Number
- NCT04566692
- Locations
- 🇺🇸
Clinical Research Center of Alabama, Birmingham, Alabama, United States
🇺🇸Research Solutions of Arizona, PC, Litchfield Park, Arizona, United States
🇺🇸Allergy Associates of The Palm Beaches, North Palm Beach, Florida, United States
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Immune Globulin (Human) 10% (Gamunex-C) PEG Process (IVIG-PEG) Compared to Gamunex-C in Participants With Primary Humoral Immunodeficiency
- Conditions
- Primary Immunodeficiency
- First Posted Date
- 2020-09-23
- Last Posted Date
- 2023-06-05
- Lead Sponsor
- Grifols Therapeutics LLC
- Target Recruit Count
- 33
- Registration Number
- NCT04561115
- Locations
- 🇺🇸
Alabama Allergy & Asthma Center, Birmingham, Alabama, United States
🇺🇸Allergy Associates of the Palm Beaches PA, North Palm Beach, Florida, United States
🇺🇸The South Bend Clinic Center for Research, South Bend, Indiana, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 9
- Next
News
BioCryst Names Charlie Gayer as New CEO Following Jon Stonehouse's Retirement Announcement
BioCryst Pharmaceuticals announced that CEO Jon Stonehouse will retire on December 31, 2025, with current Chief Commercial Officer Charlie Gayer set to succeed him as president in August and CEO in January 2026.
Cingulate Appoints Chief Legal Officer as Company Prepares FDA Filing for Novel ADHD Treatment
Cingulate Inc. has appointed Nilay Patel as Chief Legal Officer ahead of submitting a new drug application to the FDA for CTx-1301, an innovative ADHD treatment.
Grifols' Fibrinogen Concentrate BT524 Demonstrates Non-Inferiority in Phase III Trial for Surgical Bleeding
Grifols' fibrinogen concentrate BT524 met its primary endpoint in the Phase III AdFIrst trial, demonstrating non-inferiority to standard of care for treating bleeding in acquired fibrinogen deficiency during major surgery.
Sandoz Completes $11.2 Billion Spin-Off from Novartis, Becomes Independent Generics Leader
Sandoz successfully separated from Novartis and began trading independently on the SIX Swiss Exchange at CHF 24 per share, valuing the company at approximately $11.2 billion.
XL-protein Grants Worldwide License to Grifols for PASylation-Enhanced Biopharmaceutical Development
XL-protein has entered into a worldwide licensing agreement with Grifols to develop long-acting biopharmaceuticals using proprietary PASylation technology.
FDA Grants IND Clearance for Immunoglobulin Eye Drops to Treat Dry Eye Disease
The FDA has granted Investigational New Drug clearance for immunoglobulin eye drops (SLG-100/GRF312), developed by Selagine and Grifols, to treat dry eye disease in upcoming Phase II clinical trials.
IBL International and Grifols Form Strategic Partnership to Advance Specialty Diagnostics with Novel Biomarker Panels
IBL International and Grifols have partnered to develop specialized biomarker panels utilizing Grifols' single molecule counting (SMC) platform, aiming to address critical gaps in specialty diagnostics.
Biotest Reports 6% Sales Growth in 2024, FDA Approves Yimmugo for US Market
Biotest AG achieved €726.2 million in sales for 2024, a 6.1% increase driven primarily by strong performance of Intratect and Yimmugo, with EBIT reaching €94.5 million at the upper end of forecast range.
Grifols' Immunoglobulin Therapy Shows Promising Results in Post-Polio Syndrome Clinical Trial
A one-year clinical trial of Grifols' intravenous immunoglobulin therapy Flebogamma 5% DIF demonstrated significant mobility improvements in post-polio syndrome patients, with treated participants walking 12.75 meters farther in the two-minute walk test.
North Carolina Emerges as Global Bioscience Hub with $2.5B International Investment Surge
North Carolina has attracted 71 international life science companies from 20 countries, generating over $2.5 billion in investments and creating 17,000 jobs in the past five years.